Featured Research

from universities, journals, and other organizations

Researchers find metabolic clues to diabetic kidney failure

Date:
January 15, 2014
Source:
Joslin Diabetes Center
Summary:
A new study that compares the metabolic fingerprints of patients who develop ESRD versus those who don’t has furnished new clues to the disease.

January 15, 2013 -- About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease (ESRD), at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure.

However, a new study by Joslin Diabetes Center researchers that compares the metabolic fingerprints of patients who develop ESRD versus those who don't has furnished new clues to the disease.

Published in Kidney International, the study is distinctive in examining the metabolism of patients while they were still healthy or in very early stages of the disease, and in the breadth of metabolic factors analyzed, says lead author Monika Niewczas, M.D., Ph.D. Dr. Niewczas is an instructor in medicine at Harvard Medical School and a research associate in the laboratory of Andrzej Krolewski, M.D., Ph.D., head of Joslin's Section on Genetics and Epidemiology and senior author on the paper.

The analysis drew on the Joslin Kidney Study, selecting 40 patients from that study who progressed to ESRD and 40 patients who remained alive without ESRD during 8-12 years of follow-up. The Joslin researchers used global mass spectrometry to look for levels of approximately 2,400 metabolites (molecules produced during metabolism) in plasma samples from the patients.

Among the results, the scientists found 16 "uremic solute" molecules present in much higher levels in those who would go on to develop ESRD than those who would not develop the condition.

Uremic solutes are known to accumulate in plasma in the presence of kidney failure. Dr. Niewczas stresses that at the time of the sample collection kidney function was normal in the vast majority of the study subjects, suggesting that these molecules could either mark early stages of the disease or actually contribute to it.

Injury to the kidney's tubular cells is one potential mechanism by which those metabolites might lead to kidney failure. "Many of the uremic solutes that were increased are handled by the tubules and are actively secreted by those cells," Niewczas says. The high levels of these metabolites might be a sign of tubular injury, and they might also contribute to this injury.

Additionally, the researchers found a strong correlation between higher concentrations of myo-inositol, a metabolite involved in insulin signaling and in many other biological processes, and progression to ESRD.

"Metabolomics is an exciting new field, and this exploratory study is rich in very robust findings," says Niewczas. "Until now, researchers generally were focusing their studies on uremic solutes just at the single-metabolite level, but here we used a very robust, high-throughput platform that screened a few thousand metabolites instead."

"Alterations of metabolism in general are key to diabetes, and studies like this may have huge potential for unraveling new pathways which will lead to developing new drugs and new diagnostic tests," she adds.

Earlier findings by the Krolewski lab may be already headed toward clinical diagnostic use. In 2012, researchers found that high concentrations of the proteins TNFR1 and TNFR2 in blood accurately predict the risk of kidney function loss in both type 1 and type 2 diabetes 10 years in advance. This work has been licensed to a firm that develops diagnostic tests, and a clinical test will be available in the near future, says Niewczas.


Story Source:

The above story is based on materials provided by Joslin Diabetes Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Monika A Niewczas, Tammy L Sirich, Anna V Mathew, Jan Skupien, Robert P Mohney, James H Warram, Adam Smiles, Xiaoping Huang, Walker Walker, Jaeman Byun, Edward D Karoly, Elizabeth M Kensicki, Gerard T Berry, Joseph V Bonventre, Subramaniam Pennathur, Timothy W Meyer, Andrzej S Krolewski. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International, 2014; DOI: 10.1038/ki.2013.497

Cite This Page:

Joslin Diabetes Center. "Researchers find metabolic clues to diabetic kidney failure." ScienceDaily. ScienceDaily, 15 January 2014. <www.sciencedaily.com/releases/2014/01/140115095850.htm>.
Joslin Diabetes Center. (2014, January 15). Researchers find metabolic clues to diabetic kidney failure. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/01/140115095850.htm
Joslin Diabetes Center. "Researchers find metabolic clues to diabetic kidney failure." ScienceDaily. www.sciencedaily.com/releases/2014/01/140115095850.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins